Astria Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing and commercialization of therapies to patients and families affected by rare and niche allergic and immunological diseases. The Company’s lead product candidate is STAR-0215, is a potential monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema (HAE). HAE is a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen and airway. STAR-0215 is a monoclonal antibody inhibitor of plasma kallikrein, which is designed to provide long-acting attack prevention for HAE. The Company’s on-demand treatment of HAE therapy includes BERINERT, FIRAZYR, KALBITOR and RUCONEST. Its long-term preventative treatment of HAE therapy includes CINRYZE, HAEGARDA, TAKHZYRO and ORLADEYO.
Last I mentioned this, I said I thought it may start a Base 1, but wanted to watch to see if it pulled back into the transition area. Sure enough, it seems to be starting a Base 1, which isn't what I was watching for.…
Summary Looks to be just transitioning from Stage 1 to Stage 2. It's already up 40%+ out of the transition. Fundamentals are weak, but there is incoming strength for some other reason. Watch for retest of transition area or, more likely, a Base 1 to…